Can I read BRAF-Mutant NSCLC: Targeted Therapies on EtoBox?
BRAF-Mutant NSCLC: Targeted Therapies by Ruben Natarîș is a document available to read on EtoBox.
What is BRAF-Mutant NSCLC: Targeted Therapies about?
1) BRAF mutations occur in 2-4% of NSCLC cases and lead to activation of the MAPK signaling pathway, driving tumor growth. 2) Inhibiting mutant BRAF alone or in combination with MEK inhibitors has shown promise in treating BRAF-mutant melanoma and has potential to improve outcomes for NSCLC. 3) Optimizing screening strategies and choosing appropriate targeted therapies on an individual basis will be key to providing timely treatment for patients with BRAF-mutant NSCLC.
- Author
- Ruben Natarîș
- Language
- EN